What did @dr.shuayto actually say?
The creator describes Semax as a peptide that functions similarly to a drug he calls "atural", which from context appears to be Strattera (atomoxetine), a non-stimulant ADHD medication. He claims Semax increases BDNF (brain-derived neurotrophic factor), supports neuroplasticity, improves memory and focus, and modulates dopamine, serotonin, and norepinephrine. He also warns users not to combine Semax with atomoxetine, citing risks like elevated heart rate and worsened anxiety. His phrasing: "they're both neuromodulators" and "you're going to get more side effects by taking both of them."
To his credit, he does not claim Semax cures anything, and he explicitly acknowledges side effects, saying "they're not all just sunshine and rainbows." That kind of hedging is rarer in peptide content than it should be. But some of his mechanistic claims are more speculative than he lets on, and the Strattera comparison deserves real scrutiny.
Does the science back this up?
Semax's BDNF effects are the most credible part of this video, but the human evidence is thin. Most data comes from Russian preclinical and small clinical studies, which is a meaningful limitation.
A 2007 study by Dolotov et al. published in the Journal of Neurochemistry found that Semax significantly increased BDNF and its receptor TrkB in rat brain tissue, particularly in the hippocampus and cortex. That is a legitimate finding. BDNF does play a well-established role in synaptic plasticity and memory consolidation, as documented in Bhattacharya et al., 2012, Neuropharmacology. So the chain of logic, Semax raises BDNF, BDNF supports neuroplasticity, neuroplasticity may help memory, is not baseless.
The dopamine and serotonin claims are murkier. Semax is an ACTH(4-7) analog, and there is evidence it interacts with the melanocortin system, which has downstream effects on catecholamine activity. But calling it a direct dopamine and serotonin modulator in the same breath as atomoxetine, a drug with a well-characterized norepinephrine reuptake inhibition mechanism, glosses over a significant mechanistic gap. There are no published human RCTs comparing Semax to atomoxetine in ADHD populations.
What did they get wrong (or right)?
The Strattera comparison is the shakiest claim here. Atomoxetine works primarily by blocking the norepinephrine transporter, a mechanism that is well-mapped and FDA-approved. Semax influences neurotrophic and melanocortin pathways. Calling them functionally similar because both touch monoamine systems is like saying aspirin and chemotherapy are similar because both affect cell function. It is technically in the neighborhood but misleading in practice.
The drug interaction warning about combining Semax with atomoxetine is genuinely useful, even if the reasoning is imprecise. Both agents affect adrenergic tone to varying degrees. Elevated heart rate and anxiety are plausible additive effects. However, there is no published pharmacokinetic or interaction study to cite here, this is clinical inference, not documented evidence. Presenting it with the same confidence as the BDNF data is a credibility problem.
What he got right: BDNF involvement, the neuroplasticity connection, and the acknowledgment that side effects exist. That last point matters more than it sounds in a content category where peptides are often sold as consequence-free biohacking tools.
What should you actually know?
Semax is not FDA-approved. It is used in Russia as a prescription nasal spray for stroke recovery and cognitive impairment, which is a very different clinical context than ADHD optimization or focus enhancement in healthy adults. The leap from "helps stroke patients" to "boosts your memory" is one the research has not yet earned.
If you are on atomoxetine or any noradrenergic medication, the caution about adding Semax is reasonable, but it should be a conversation with a prescriber, not a decision made based on a TikTok video. The interaction has not been formally studied, which means the risk profile is unknown, not zero.
Compounded versions of Semax available through US telehealth platforms are not equivalent to the Russian pharmaceutical formulation. Potency, purity, and delivery method vary. Anyone considering Semax should be working with a clinician who can monitor cardiovascular and neurological response, not self-dosing based on content that correctly identifies BDNF but skips over the part where human trial data is almost entirely absent.
Our overall read
This video is better than most peptide content on TikTok. The BDNF mechanism is real, the side effect acknowledgment is refreshing, and the drug interaction warning is clinically sensible even if under-supported. But the atomoxetine comparison oversimplifies two very different pharmacological profiles, and the confidence level throughout does not match the quality of available human evidence. Credit where it is due, and skepticism where the data runs out.